Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours

Abstract

Background: Adult ovarian granulosa cell tumours (GCT) are the most common subtype of ovarian sex cord-stromal tumours. Forkhead transcription factor FOXL2 is required for development and function of normal granulosa cells, including proliferation and ovarian hormone synthesis. A single somatic missense mutation in FOXL2, c.402C > G (p.Cys134Trp), has previously been identified in the majority of GCT and is a pathognomonic marker for this tumour type. NOTCH activation contributes to GCT survival in preclinical models, and NOTCH2 and NOTCH3 are critical for embryonic development of the ovary and function of the ovarian follicle. Nirogacestat is a potent, selective, noncompetitive inhibitor of gamma secretase, which inhibits NOTCH pathway signalling. Treatment of GCT with nirogacestat was predicted to inhibit granulosa cell survival.

Methods: A Phase II clinical trial was conducted to assess antitumour activity of nirogacestat in adult patients with relapsed/refractory ovarian GCT (NCT05348356). This study enrolled 53 patients; all were evaluable for efficacy and safety. Endpoints included objective response rate by Response Evaluation Criteria in Solid Tumors v1.1 and 6-month progression-free survival (PFS6). Fresh or archival tumour samples were analysed for mutational profiling.

Results: Patients received a median of 5 prior lines of therapy (range, 1–13) and a median of 3.7 months of treatment (range, 0–20 months). A decrease in tumour burden was seen in 16 (30%) patients; however, there were no confirmed objective responses. Thirty-one (58%) patients had stable disease; 18 (34%) had progressive disease. Eleven (21%) patients achieved PFS6. No correlations with disease stability were found with baseline clinical characteristics. All 3 patients who had an activating NOTCH1 mutation achieved PFS6.

Conclusions: In patients with heavily pretreated GCT, nirogacestat treatment resulted in durable disease stabilisation of at least 7 weeks for 58% of patients, with 21% achieving PFS6, including the 3 patients whose tumours had an activating NOTCH1 mutation.

Keywords

gamma secretase inhibitors / mutational profiling / NOTCH / tumour recurrence

References

[1] Fuller PJ, Leung D, Chu S. Genetics and genomics of ovarian sex cord-stromal tumors. Clin Genet. 2017; 91(2): 285-291.

[2] Jamieson S, Fuller PJ. Molecular pathogenesis of granulosa cell tumors of the ovary. Endocr Rev. 2012; 33(1): 109-144.

[3] Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003; 21(6): 1180-1189.

[4] Li J, Chu R, Chen Z, et al. Progress in the management of ovarian granulosa cell tumor: a review. Acta Obstet Gynecol Scand. 2021; 100(10): 1771-1778.

[5] Ayhan A, Salman MC, Velipasaoglu M, Sakinci M, Yuce K. Prognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases. J Gynecol Oncol. 2009; 20(3): 158-163.

[6] Bryk S, Farkkila A, Butzow R, et al. Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors. Gynecol Oncol. 2016; 143(3): 571-577.

[7] Zhao D, Zhang Y, Ou Z, Zhang R, Zheng S, Li B. Characteristics and treatment results of recurrence in adult-type granulosa cell tumor of ovary. J Ovarian Res. 2020; 13(1): 19.

[8] Wang PH, Sun HD, Lin H, et al. Outcome of patients with recurrent adult-type granulosa cell tumors–a Taiwanese Gynecologic Oncology Group study. Taiwan J Obstet Gynecol. 2015; 54(3): 253-259.

[9] Dridi M, Chraiet N, Batti R, et al. Granulosa cell tumor of the ovary: a retrospective study of 31 cases and a review of the literature. Int J Surg Oncol. 2018; 2018:4547892.

[10] Mangili G, Ottolina J, Gadducci A, et al. Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary. Br J Cancer. 2013; 109(1): 29-34.

[11] Hauspy J, Beiner ME, Harley I, et al. Role of adjuvant radiotherapy in granulosa cell tumors of the ovary. Int J Radiat Oncol Biol Phys. 2011; 79(3): 770-774.

[12] Wolf JK, Mullen J, Eifel PJ, Burke TW, Levenback C, Gershenson DM. Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Gynecol Oncol. 1999; 73(1): 35-41.

[13] Brink GJ, Groeneweg JW, Hooft L, Zweemer RP, Witteveen PO. Response to systemic therapies in ovarian adult granulosa cell tumors: a literature review. Cancers (Basel). 2022; 14(12): 2998.

[14] Hardy RD, Bell JG, Nicely CJ, Reid GC. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol. 2005; 96(3): 865-869.

[15] van Meurs HS, van Lonkhuijzen LR, Limpens J, van der Velden J, Buist MR. Hormone therapy in ovarian granulosa cell tumors: a systematic review. Gynecol Oncol. 2014; 134(1): 196-205.

[16] Andres S, Finch L, Iasonos A, et al. Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer. Gynecol Oncol. 2024; 189: 30-36.

[17] Finch L, Andres S, Iasonos A, et al. Basket study of oral progesterone antagonist onapristone extended-release in combination with anastrozole in progesterone receptor-positive recurrent adult-type granulosa cell tumor of the ovary. Int J Gynecol Cancer. 2025; 35(1):100005.

[18] Banerjee SN, Tang M, O'Connell RL, et al. A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: the PARAGON/ANZGOG 0903 trial. Gynecol Oncol. 2021; 163(1): 72-78.

[19] Brown J, Brady WE, Schink J, et al. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer. 2014; 120(3): 344-351.

[20] Ray-Coquard I, Harter P, Lorusso D, et al. Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors: the ALIENOR/ENGOT-ov7 randomized clinical trial. JAMA Oncol. 2020; 6(12): 1923-1930.

[21] Shah SP, Köbel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009; 360(26): 2719-2729.

[22] Schrader KA, Gorbatcheva B, Senz J, et al. The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors. PLoS One. 2009; 4(11):e7988.

[23] Al-Agha OM, Huwait HF, Chow C, et al. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol. 2011; 35(4): 484-494.

[24] Kim MS, Hur SY, Yoo NJ, Lee SH. Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. J Pathol. 2010; 221(2): 147-152.

[25] Jamieson S, Butzow R, Andersson N, et al. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Mod Pathol. 2010; 23(11): 1477-1485.

[26] D'Angelo E, Mozos A, Nakayama D, et al. Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary. Mod Pathol. 2011; 24(10): 1360-1367.

[27] Pilsworth JA, Cochrane DR, Xia Z, et al. TERT promoter mutation in adult granulosa cell tumor of the ovary. Mod Pathol. 2018; 31(7): 1107-1115.

[28] Alexiadis M, Rowley SM, Chu S, et al. Mutational landscape of ovarian adult granulosa cell tumors from whole exome and targeted TERT promoter sequencing. Mol Cancer Res. 2019; 17(1): 177-185.

[29] da Cruz Paula A, da Silva EM, Segura SE, et al. Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary. Mod Pathol. 2020; 33(8): 1606-1617.

[30] Hillman RT, Lin DI, Lawson B, Gershenson DM. Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors. Gynecol Oncol. 2021; 162(3): 728-734.

[31] Hillman RT, Celestino J, Terranova C, et al. KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary. Nat Commun. 2018; 9(1): 2496.

[32] Irusta G, Pazos MC, Abramovich D, De Zuniga I, Parborell F, Tesone M. Effects of an inhibitor of the gamma-secretase complex on proliferation and apoptotic parameters in a FOXL2-mutated granulosa tumor cell line (KGN). Biol Reprod. 2013; 89(1): 9.

[33] Vanorny DA, Mayo KE. The role of Notch signaling in the mammalian ovary. Reproduction. 2017; 153(6): R187-R204.

[34] Fortini ME. Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. Nat Rev Mol Cell Biol. 2002; 3(9): 673-684.

[35] Terauchi KJ, Shigeta Y, Iguchi T, Sato T. Role of Notch signaling in granulosa cell proliferation and polyovular follicle induction during folliculogenesis in mouse ovary. Cell Tissue Res. 2016; 365(1): 197-208.

[36] Wang LQ, Liu JC, Chen CL, et al. Regulation of primordial follicle recruitment by cross-talk between the Notch and phosphatase and tensin homologue (PTEN)/AKT pathways. Reprod Fertil Dev. 2016; 28(6): 700-712.

[37] Zhang CP, Yang JL, Zhang J, et al. Notch signaling is involved in ovarian follicle development by regulating granulosa cell proliferation. Endocrinology. 2011; 152(6): 2437-2447.

[38] Chauvin MY, Pépin D, Pre-clinical evaluation of the gamma-secretase inhibitor nirogacestat in an adult-type ovarian granulosa cell tumor model. Presented at: AACR Special Conference on Ovarian Cancer; October 5–7, 2023; Boston, MA.

[39] Gounder M, Ratan R, Alcindor T, et al. Nirogacestat, a gamma-secretase inhibitor for desmoid tumors. N Engl J Med. 2023; 388(10): 898-912.

[40] Keam SJ. Nirogacestat: first approval. Drugs. 2024; 84(3): 355-361.

[41] Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016; 32(18): 2847-2849.

[42] Gu Z. Complex heatmap visualization. Imeta. 2022; 1(3):e43.

[43] Haltia UM, Pihlajoki M, Andersson N, et al. Functional profiling of FSH and estradiol in ovarian granulosa cell tumors. J Endocr Soc. 2020; 4(4):bvaa034.

[44] Geerts I, Vergote I, Neven P, Billen J. The role of inhibins B and antimullerian hormone for diagnosis and follow-up of granulosa cell tumors. Int J Gynecol Cancer. 2009; 19(5): 847-855.

[45] Tang H, Thomas PD. PANTHER-PSEP: predicting disease-causing genetic variants using position-specific evolutionary preservation. Bioinformatics. 2016; 32(14): 2230-2232.

[46] Shamsudeen S, Dunton CJ. Granulosa theca cell tumors of the ovary. StatPearls. StatPearls Publishing; 2023.

[47] Kummar S, O'Sullivan Coyne G, Do KT, et al. Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). J Clin Oncol. 2017; 35(14): 1561-1569.

[48] Messersmith WA, Shapiro GI, Cleary JM, et al. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014. Clin Cancer Res. 2015; 21(1): 60-67.

[49] Cravero K, Pantone MV, Shin DH, et al. NOTCH1 PEST domain variants are responsive to standard of care treatments despite distinct transformative properties in a breast cancer model. Oncotarget. 2022; 13: 373-386.

[50] Wang K, Zhang Q, Li D, et al. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a gamma-secretase inhibitor. Clin Cancer Res. 2015; 21(6): 1487-1496.

[51] Boerboom D, Paquet M, Hsieh M, et al. Misregulated Wnt/beta-catenin signaling leads to ovarian granulosa cell tumor development. Cancer Res. 2005; 65(20): 9206-9215.

[52] Carothers AM, Rizvi H, Hasson RM, et al. Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors. Cancer Res. 2012; 72(1): 346-355.

[53] Roze J, Monroe G, Kutzera J, et al. Whole genome analysis of ovarian granulosa cell tumors reveals tumor heterogeneity and a high-grade TP53-specific subgroup. Cancers (Basel). 2020; 12(5): 1308.

[54] Michalkova R, Safanda A, Hajkova N, et al. The molecular landscape of 227 adult granulosa cell tumors of the ovary: insights into the progression from primary to recurrence. Lab Invest. 2025; 105(3):102201.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.